Compare Hershey Co (HSY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs TG Therapeutics Inc — how do they compare? Hershey Co trades at $184.1 (market cap $37.40B), while TG Therapeutics Inc trades at $48.55 (market cap $7.34B). The key difference: Hershey Co is far larger — about 5.1× TG Therapeutics Inc's market cap, and Hershey Co pays a 3.12% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HSY | TGTX | |
|---|---|---|
Market Cap | $37.40B | $7.34B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $59.06 |
52-Week Low | $162.31 | $26.94 |
Enterprise Value | $42.53B | $7.54B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $186.12, up 2.27% on the day, near its consensus price target of $196.78. The stock shows bullish momentum with recent earnings beats, including Q2 2026 EPS of $1.90 versus $1.43 expected. Fundamentals reflect strong profitability with a net income margin of 12.24% and ROE of 32.81%, though 2025 net income dipped to $883 million. Technical indicators are mixed, with RSI suggesting overbought conditions but moving averages supporting a bullish trend.
The outlook is cautiously optimistic, driven by margin recovery from lower cocoa costs and raised full-year guidance. Key risks include volume declines and competitive pressures in snacks. Analyst sentiment is mixed with 69% hold ratings, but recent upgrades highlight improving fundamentals. The stock offers dividend income with a $1.45 quarterly payout, but investors should monitor execution against guidance amid economic headwinds.
TG Therapeutics (TGTX) trades at $49.50, down 0.8% with a bearish technical signal. The company reported strong revenue growth with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though earnings have missed expectations for three consecutive quarters. Analyst consensus remains bullish with 84.6% buy ratings and a $63.75 price target, representing 29% upside potential from current levels.
The outlook is mixed with strong revenue momentum from BRIUMVI offset by earnings misses and negative cash flow. Key risks include ongoing earnings underperformance, shareholder litigation, and high valuation multiples. The stock offers growth potential but requires careful monitoring of execution and profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
